Centene (CNC) On Strong Q2 And Higher 2026 Guidance Looks Undervalued
Centene (CNC) is back in focus after second quarter 2026 results came in stronger than expected. The company moved from a loss a year ago and raised its 2026 revenue and adjusted EPS guidance.
The share price of Centene has climbed 54.98% year to date to US$64.75, with a 30 day share price return of 4.74% and a 90 day gain of 8.64%. Over the past year, total shareholder return of 122.97% points to strong momentum, while recent CFO succession news and upgraded valuation models suggest investors are reacting mainly to the improved earnings profile and guidance rather than governance concerns.
Compare Centene's momentum and guidance upgrade with other health insurers by scanning our hand picked list of solid balance sheet and fundamentals (51 results) that may benefit from similar earnings resilience and capital discipline.
Bulls point to Centene's sharp share price gain and higher guidance as evidence the earnings reset is real. Bears see policy risk and past losses as reasons to be cautious. Which case does the current valuation lean toward next?
Most Popular Narrative: 9.7% Undervalued
Analysts’ most followed narrative puts Centene’s fair value at $71.67, above the last close of $64.75. This frames the recent rally in a different light.
Analysts expect earnings to reach $3.2 billion (and earnings per share of $6.67) by about August 2029, compared to $5.1 billion of losses today. However, there is some disagreement amongst the analysts, with the more bullish ones expecting earnings as high as $4.3 billion.
If you want to understand why this narrative points to a higher earnings run rate for Centene, the story focuses on improving margins, steadier revenue growth and a different profit mix than today.
Result: Fair Value of $71.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Centene's story still depends on stable Medicaid policy and medical cost trends, which could quickly challenge the 9.7% undervalued narrative if they turn.
Find out about the key risks to this Centene narrative.
Next Steps
With Centene's mix of encouraging guidance and policy questions in mind, move quickly to test the narrative against the underlying data, and weigh both sides for yourself using the full breakdown of 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Centene?
Centene's latest move may have caught your eye, but your next strong idea could be waiting in a very different corner of the market.
- Target potential mispricings by scanning companies that our data flags as stronger value candidates using the 45 high quality undervalued stocks.
- Strengthen your defensive side by reviewing a 74 resilient stocks with low risk scores that may help stabilise your portfolio when markets turn choppy.
- Get a head start on potential future leaders by checking out a 19 high quality undiscovered gems before they hit everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com